CN107635563A - 抗菌化合物 - Google Patents

抗菌化合物 Download PDF

Info

Publication number
CN107635563A
CN107635563A CN201580073500.0A CN201580073500A CN107635563A CN 107635563 A CN107635563 A CN 107635563A CN 201580073500 A CN201580073500 A CN 201580073500A CN 107635563 A CN107635563 A CN 107635563A
Authority
CN
China
Prior art keywords
compound
niclosamide
salicylamide
bacterial
salicylamide compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580073500.0A
Other languages
English (en)
Chinese (zh)
Inventor
J·N·科帕
D·F·阿克利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Victoria Link Ltd
Original Assignee
Victoria Link Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Victoria Link Ltd filed Critical Victoria Link Ltd
Publication of CN107635563A publication Critical patent/CN107635563A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580073500.0A 2014-11-17 2015-11-17 抗菌化合物 Pending CN107635563A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ70200114 2014-11-17
NZ702001 2014-11-17
PCT/NZ2015/050192 WO2016080846A1 (en) 2014-11-17 2015-11-17 Antibacterial compounds

Publications (1)

Publication Number Publication Date
CN107635563A true CN107635563A (zh) 2018-01-26

Family

ID=56014262

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580073500.0A Pending CN107635563A (zh) 2014-11-17 2015-11-17 抗菌化合物

Country Status (5)

Country Link
US (1) US20190328687A1 (enExample)
EP (1) EP3220919A4 (enExample)
JP (1) JP2018500387A (enExample)
CN (1) CN107635563A (enExample)
WO (1) WO2016080846A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112716944A (zh) * 2021-02-25 2021-04-30 成都大学 硝基咪唑类化合物在制备抑制细菌群体感应的药物中的应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3967312A1 (en) 2014-09-12 2022-03-16 UNION therapeutics A/S Antibacterial use of halogenated salicylanilides
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
GB201604484D0 (en) 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
GB201805453D0 (en) * 2018-04-03 2018-05-16 Antibiotx As Novel use
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
CN108998499A (zh) * 2018-06-05 2018-12-14 上海海洋大学 一种快速测定生物被膜中大肠杆菌对抗生素耐药性的方法
WO2020176067A1 (en) 2019-02-25 2020-09-03 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with h. pylori using a halogenated salicylanilide
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
IL289072B2 (en) * 2019-06-19 2025-06-01 QBiotics Pty Ltd Biofilm disruption

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60127285T2 (de) * 2000-10-02 2007-12-20 The Research Foundation Of State University Of New York At Buffalo Naphthylsalicylanilide als antimikrobielle und entzündungshemmende mittel
US7994225B2 (en) * 2004-03-17 2011-08-09 Rempex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections
US7879795B2 (en) * 2004-05-21 2011-02-01 Mpex Pharmaceuticals, Inc. Enhancement of tigecycline potency using efflux pump inhibitors
WO2014018932A2 (en) * 2012-07-27 2014-01-30 Bunt Antonius Martinus Gustave Effluz inhibitor compositions and methods of treatment using the same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112716944A (zh) * 2021-02-25 2021-04-30 成都大学 硝基咪唑类化合物在制备抑制细菌群体感应的药物中的应用

Also Published As

Publication number Publication date
WO2016080846A1 (en) 2016-05-26
JP2018500387A (ja) 2018-01-11
US20190328687A1 (en) 2019-10-31
EP3220919A1 (en) 2017-09-27
EP3220919A4 (en) 2018-07-18

Similar Documents

Publication Publication Date Title
CN107635563A (zh) 抗菌化合物
AlMatar et al. Efflux pump inhibitors: new updates
CA2910756C (en) Compounds and methods of treating infections
Thomann et al. Application of dual inhibition concept within looped autoregulatory systems toward antivirulence agents against Pseudomonas aeruginosa infections
JP6142076B2 (ja) 抗微生物性増強剤
US10322112B2 (en) Compound combinations for attenuation of bacterial virulence
EP1079819B1 (en) Hydroxamic acid derivatives as antibacterials
US12161630B2 (en) Methods to control infection using new generation small molecule growth inhibitors
CN107980000A (zh) 包含抗菌剂的药物组合物
EP2969003A1 (en) Methods and compositions for bacteria infections
US20130331413A1 (en) Defensin-like molecules as novel antimicrobial agents
JP2015523997A (ja) 微生物バイオフィルム破壊のためのクルクミン誘導体
US11040949B2 (en) Compounds affecting pigment production and methods for treatment of bacterial diseases
US11052078B2 (en) Compounds affecting pigment production and methods for treatment of bacterial diseases
WO2011060976A1 (en) Tryptamine-derived compounds as antibacterial agents
CN106794250A (zh) 包含抗菌剂的药物组合物
US11690824B2 (en) Antibacterial compounds
US20220289677A1 (en) Dna primase and gyrase inhibitors
US20230278971A1 (en) Compounds affecting pigment production and methods for treatment of bacterial diseases
WO2012074490A1 (en) Control of bacterial growth
WO2019147987A1 (en) Antimicrobial compositions and methods of using the same
US20210309622A1 (en) Compounds affecting pigment production and methods for treatment of bacterial diseases
US10772900B2 (en) Drug target for treating veterinary infections and methods of using same
Godballe Mode of Action Studies on Synthetic Antimicrobial Peptides
ES2804500T3 (es) Composiciones farmacéuticas que comprenden agentes antibacterianos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180126